HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Today's Posts

 
 
Thread Tools Display Modes
Prev Previous Post   Next Post Next
Old 03-31-2004, 12:01 AM   #1
Paul
Guest
 
Posts: n/a
At the 95th annual American Association for Cancer Research (AACR) meeting in Orlando USA AstraZeneca Plc reported new gefitinib (IRESSA(tm) ZD1839) data exploring mechanisms of drug activity and resistance as well as new data relating to novel anti-angiogenesis drugs ZD6474 and AZD2171 that have potential in a wide range of tumors.

  Reply With Quote
 


Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 05:41 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter